drug

ACR-2316

1 story · latest Aug 12, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Acrivon Therapeutics

Timeline

Acrivon reports Q2 2026 results, flags ACR-368 interim data for second half of 2026

Aug 12Quarterly updateACR-2316 Acrivon Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.